Akzo Nobel (ENXTAM:AKZA) Stock Faces One Off Driven Margin Lift Challenging Earnings Quality Narratives

Akzo Nobel (ENXTAM:AKZA) has reported Q2 2026 revenue of €2.6 billion and basic EPS of €0.82, with trailing 12 month figures sitting at €9.9 billion of revenue and EPS of €3.73, alongside earnings growth of 53.7% over the past year. The company has seen quarterly revenue move from €2.63 billion and EPS of €0.73 in Q2 2025 to €2.59 billion and EPS of €0.82 in Q2 2026, while trailing net profit margin has shifted from 3.9% to 6.4%, helped by a one off gain of €357 million. Overall, Akzo Nobel is reporting cleaner margins on the latest numbers, but investors will be weighing how much of that profitability reflects core operations versus one off effects.

See our full analysis for Akzo Nobel.

With the headline figures in place, the next step is to see how these results stack up against the widely followed narratives around Akzo Nobel’s growth drivers, risks and earnings quality.

See what the community is saying about Akzo Nobel

Margins Look Cleaner, But €357m One Off Matters

• Over the last 12 months Akzo Nobel generated €9.9b of revenue and €638 million of net income from continuing operations, which translates into a 6.4% net margin compared with 3.9% a year earlier, with a €357 million one off gain playing a major role in that uplift.
• Supporters of the bullish narrative point to higher margins as a foundation for future earnings, yet the fact that trailing net income of €638 million includes that €357 million one off item means a large share of the 53.7% year on year earnings growth is not from recurring operations, so any thesis built on margin strength alone needs to separate this one time boost from ongoing profitability.

Q2 2026 Profitability Versus Volatile Recent History

• Q2 2026 delivered €2,589 million of revenue and €0.82 of EPS, which sits in the context of a very uneven prior year that ranged from a loss of €193 million in Q3 2025 to €598 million of net income in Q4 2025, highlighting how bumpy recent quarterly profitability has been.
• Bears highlight this patchy track record, arguing that a period including a loss in Q3 2025 and an outsized profit in Q4 2025, alongside the current 6.4% trailing margin, suggests earnings quality is mixed. Yet Q2 2026 EPS of €0.82 and net income of €140 million from continuing operations also show that Akzo Nobel is currently profitable without relying on extreme swings, so the cautious view has to weigh those past fluctuations against the more stable recent quarters.

For readers who think those ups and downs could matter more than the latest headline beat or miss, it is worth seeing how skeptics frame the downside case in detail before taking a stance on Akzo Nobel. 🐻 Akzo Nobel Bear Case

Valuation Signals Versus Balance Sheet Pressure

• Akzo Nobel trades at €58.14 per share, on a 15.6x P/E, while the DCF fair value is quoted at €93.11 and peers trade on around 55.8x with the wider European Chemicals industry at about 20x, so the stock screens as cheaper on both a DCF and relative P/E basis.
• Consensus narrative often leans on this apparent discount, yet the same analysis flags that operating cash flow does not fully cover debt and that recent share price moves have been highly volatile. This means the case that the €58.14 price is simply a mispricing has to be balanced against these financial and market risks that can justify a lower multiple even when headline valuation metrics look appealing.

If you are weighing whether that valuation gap reflects opportunity or just compensation for risk, it helps to see how bullish investors connect Akzo Nobel’s cost programs, planned merger and margin targets back to those numbers. 🐂 Akzo Nobel Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Akzo Nobel on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed messages on Akzo Nobel’s risks and rewards so far, or a clear story starting to form in your mind? Take a closer look at the data, pressure test both sides of the argument, and then ground your own view in the 4 key rewards and 4 important warning signs.

See What Else Is Out There

Akzo Nobel’s current story includes uneven recent profitability, reliance on a €357 million one off gain, and operating cash flow that does not fully cover debt.

If that mix of bumpy earnings and balance sheet pressure has you looking for steadier ideas, check out solid balance sheet and fundamentals stocks screener (420 results) to focus on companies with stronger financial foundations and potentially lower financing risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com